Pharmacogenetics in cancer treatment

被引：85

作者：

Nagasubramanian, R ^{[1
]}

Innocenti, F

Ratain, MJ

机构：

[1] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA

[2] Univ Chicago, Dept Med, Comm Clin Pharmacol & Pharmacogenom, Chicago, IL 60637 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2003年 / 54卷

关键词：

polymorphisms; drug metabolism; chemotherapy; drug response; toxicity;

D O I：

10.1146/annurev.med.54.101601.152352

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Interindividual variability in the efficacy and toxicity of drug therapy is associated with polymorphisms in genes encoding drug-metabolizing enzymes, transporters, or drug targets. Pharmacogenetics aims to identify individuals predisposed to high risk of toxicity from conventional doses of cancer chemotherapeutic agents. We review the role of genetic polymorphisms in UGT1A1 and TPMT, as well as mutations in DPD, in influencing drug disposition and toxicity. Recent studies show that pharmacogenetic determinants may also influence treatment outcomes. We discuss the clinical significance of polymorphisms in TS, MTHFR, and FCGR3A, as well as the polymorphic DNA repair genes XPD and XRCC1, in influencing reponse to chemotherapy and survival outcomes. Finally, the potential implications of transporter pharmacogenetics in influencing drug bioavailability are addressed.

引用

页码：437 / 452

页数：16

共 77 条

[1] MDR1 pharmacogenetics:: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J].

Ameyaw, MM ;

Regateiro, F ;

Li, T ;

Liu, XH ;

Tariq, M ;

Mobarek, A ;

Thornton, N ;

Folayan, GO ;

Githang'a, J ;

Indalo, A ;

Ofori-Adjei, D ;

Price-Evans, DA ;

McLeod, HL .

PHARMACOGENETICS, 2001, 11 (03) :217-221

[2]

Ando Y, 2000, CANCER RES, V60, P6921

[3] Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil [J].

Baker, SD ;

Diasio, RB ;

O'Reilly, S ;

Lucas, VS ;

Khor, SP ;

Sartorius, SE ;

Donehower, RC ;

Grochow, LB ;

Spector, T ;

Hohneker, JA ;

Rowinsky, EK .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :915-926

[4] Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter:: A balanced polymorphism for regulation of bilirubin metabolism? [J].

Beutler, E ;

Gelbart, T ;

Demina, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :8170-8174

[5]

BOSMA PJ, 1994, J BIOL CHEM, V269, P17960

[6] THE GENETIC-BASIS OF THE REDUCED EXPRESSION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE-1 IN GILBERTS-SYNDROME [J].

BOSMA, PJ ;

CHOWDHURY, JR ;

BAKKER, C ;

GANTLA, S ;

DEBOER, A ;

OOSTRA, BA ;

LINDHOUT, D ;

TYTGAT, GNJ ;

JANSEN, PLM ;

ELFERINK, RPJO ;

CHOWDHURY, NR .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (18) :1171-1175

[7] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].

Cartron, G ;

Dacheux, L ;

Salles, G ;

Solal-Celigny, P ;

Bardos, P ;

Colombat, P ;

Watier, H .

BLOOD, 2002, 99 (03) :754-758

[8]

Castro E, 1999, AM J MED GENET, V82, P399, DOI 10.1002/(SICI)1096-8628(19990219)82:5<399::AID-AJMG8>3.0.CO

[9]

2-R

[10] Known variant DPYD alleles do not explain DPD deficiency in cancer patients [J].

Collie-Duguid, ESR ;

Etienne, MC ;

Milano, G ;

McLeod, HL .

PHARMACOGENETICS, 2000, 10 (03) :217-223

← 1 2 3 4 5 6 7 8 →